Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT04823377
Active, not recruiting Not applicable

Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.

NCT04823377 · tracked via the Priya Life Science France tracker
Sponsor
Institut Curie
Phase
Not applicable
Started
2021-09-24
Last updated
2025-11-28

Condition(s) studied

Carcinoma, Non-Small-Cell LungAdvanced Cancer

Investigational drug(s) / intervention(s)

Usual careOptimization of the medical decision

Usual care: Patients receiving systemic anticancer treatment in their last days of life

Optimization of the medical decision: Impact of the use of an optimization device of the decision of cancer treatment on aggressiveness of end of life care

Study summary

Sequential comparative prospective interventional study evaluating the impact of the use of an optimization device of the decision of cancer treatment on aggressiveness of end of life care. Comparison between a first period, period (A), of care as usual and a second period, period (B), of systematic and iterative use of a device for optimizing the decision to continue an anti-cancer treatment.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Histologically or cytologically proven non-small-cell lung carcinoma (NSCLC) including NSCLC with oncogene addiction. 2. Stage IV or IIB/IIIC non irradiable (8th classification TNM, UICC 2015) 3. Patient having completed at least one line of chemotherapy in the context of metastatic disease (or in the context of locoregional disease if the last chemotherapy was less than 6 months ago). 4. ECOG Performance Status ≥ 2. 5. Age ≥ 18. 6. Written informed consent. 7. Patient capable, according to the investigator, to comply with the requirements of the study. Exclusion Criteria: 1. Small Cell Lung Cancer (including mixed forms). 2. Patient with NSCLC for whom a decision has already been made to permanently discontinue all systemic cancer treatment. 3. Impossible follow up for geographical, social or psychological reason. 4. Inability to answer a questionnaire (language or neurological barrier). 5. Patient under guardianship. 6. Patient being treated in a therapeutic trial. 7. Patient not covered by social security. -

Primary outcome measure(s)

  • Percentage of patients receiving systemic anticancer treatment in their last days of life — 24 months
    Comparison of the percentage of patients receiving systemic anticancer treatment in their last 30 days of life during each period

Trial sites (25)

FacilityCityRegionStatus
CH Abbeville Abbeville France
CH du Pays d'Aix Aix-en-Provence France
CHU Amiens - Hôpital Sud Amiens France
CHU Angers Angers France
CHR Metz-Thionville - Hôpital de Mercy Ars-Laquenexy France
CH Henri Duffaut Avignon Avignon France
Institut Sainte-Catherine Avignon France
AP-HP Ambroise Paré Boulogne-Billancourt France
CHI de Compiègne-Noyon Compiègne France
CHU Sud Francilien Corbeil-Essonnes France
Clinique des Cèdres Cornebarrieu France
CH Intercommunal de Créteil Créteil France
CGFL Dijon France
CHU Grenoble Alpes Grenoble France
CHD Vendée La Roche-sur-Yon France
CHRU Lille Lille France
Centre Léon Bérard Lyon France
Institut Curie Paris France
AP-HP Cochin Paris France
AP-HP Bichat Paris France
AP-HP Tenon Paris France
Institut Curie Saint-Cloud France
CH Saint-Malo St-Malo France
Hôpital Foch Suresnes France
Clinique Tessier Valenciennes France

More Institut Curie trials in France

Optimizing Bronchopulmonary Cancer Screening Recruiting
Skin Reactions Related to Thoracic Implantable Chamber Dressings Recruiting
Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME) Recruiting
Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI) Recruiting
Omission of Surgery for Triple-negative Breast Cancer in Complete Response After Neoadjuvant Chemo-immunotherapy Starting soon

Other trials for the same condition

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer Recruiting
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors Recruiting
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors Recruiting
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer Active, not recruiting
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04823377 on ClinicalTrials.gov ↗ ← All trials in France